Early day motion tabled by primary sponsor Grahame Morris (Labour), on Wednesday, 11 March 2026, in the House of Commons. It is signed by 9 members in total.
Ketamine
That this House notes with concern the increased problematic use of ketamine, particularly among young people; further notes that its severe impacts can include cognitive impairment, psychological difficulties and physical damage to the bladder, kidneys and urinary tract, leading to dependency and contributing to deaths; recognises that those affected may require incontinence pads or surgery; pays tribute to those providing peer-support in friendly, safe groups free from stigma; supports the recommendations of the Advisory Council on the Misuse of Drugs (ACMD) advising against the reclassification of the drug from a Class B to a Class A controlled substance; recognises that previous punitive policies have proven to be ineffective and often counter-productive; advocates a public health-centred harm reduction approach, providing access to evidence-based education and effective treatment; and urges the Government to adopt the recommendations of the ACMD, raise awareness of ketamine-related harms and promote the expansion of education, treatment and support services.
Secondary information
- Type
- Early day motion
- Reference
- 2943
- Session
- 2024-26
- Other sponsors
- John McDonnell
- Carla Denyer
- Bob Blackman
- Siân Berry
- Brian Leishman
- Subjects
- Misuse Ketamine
- Link
- View this Early day motion on edm.parliament.uk
Librarians' tools
- Timestamp
- 2026-04-09 16:11:48 +0100
- URI
- http://data.parliament.uk/edms/65394
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/edms/65394
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/edms/65394